Department of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China.
Heilongjiang Key Laboratory for Animal Disease Control and Pharmaceutical Development, Harbin 150030, China.
Molecules. 2023 May 23;28(11):4267. doi: 10.3390/molecules28114267.
In this study, a series of novel 3-(5-fluoropyridine-3-yl)-2-oxazolidinone derivatives were designed and synthesized based on compounds previously reported, and their antibacterial activity was investigated. Then their antibacterial activity was investigated for the first time. Preliminary screening results showed that all these compounds exhibited antibacterial activity against gram-positive bacteria, including 7 drug-sensitive strains and 4 drug-resistant strains, among which compound exhibited an 8-fold stronger inhibitory effect than linezolid, with a minimum inhibitory concentration (MIC) value of 0.25 µg/mL. Further molecular docking studies predicted the possible binding mode between active compound and the target. Interestingly, these compounds could not only hamper the formation of biofilms, but also have better safety, as confirmed by cytotoxicity experiments. All these results indicate that these 3-(5-fluoropyridine-3-yl)-2-oxazolidinone derivatives have the potential to be developed into novel candidates for the treatment of gram-positive bacterial infections.
在这项研究中,基于先前报道的化合物,设计并合成了一系列新型 3-(5-氟吡啶-3-基)-2-恶唑烷酮衍生物,并研究了它们的抗菌活性。这是首次对其抗菌活性进行研究。初步筛选结果表明,所有这些化合物对革兰氏阳性菌均具有抗菌活性,包括 7 株药敏株和 4 株耐药株,其中化合物 对利奈唑胺的抑制作用增强了 8 倍,最低抑菌浓度(MIC)值为 0.25 µg/mL。进一步的分子对接研究预测了活性化合物与靶标的可能结合模式。有趣的是,这些化合物不仅可以阻止生物膜的形成,而且通过细胞毒性实验证实它们具有更好的安全性。所有这些结果表明,这些 3-(5-氟吡啶-3-基)-2-恶唑烷酮衍生物有可能被开发成为治疗革兰氏阳性菌感染的新型候选药物。